← Back to patent-cliff list
Flonoltinib maleate
Tier C — Watch / tradeFlonoltinib maleate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK2, FLT3, CDK6
Indications (approved)：Myelofibrosis, 丝虫病, 红细胞增多症, Essential thrombocythaemia, Polycythaemia vera, Myeloproliferative neoplasm, Neoplasm, 噬血细胞性淋巴组织细胞增多症
Regional status
US
Phase II
2025-05-16
EU
-
China
Phase III
2026-02-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Flonoltinib maleate?
Approved indications include: Myelofibrosis, 丝虫病, 红细胞增多症, Essential thrombocythaemia, Polycythaemia vera, Myeloproliferative neoplasm, Neoplasm, 噬血细胞性淋巴组织细胞增多症.
When does the Flonoltinib maleate patent expire?
No public expiry year is available for Flonoltinib maleate yet; this page updates once verified.
How do I get a quote for Flonoltinib maleate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29